In fact, you can save up to 52 percent on the daily costs of your medications if
you purchase generic drugs instead of branded ones.
Not exact matches
Making matters worse, Teva was saddled with $ 35 billion debt from its $ 40.5 billion
purchase in 2016 of Allergan's
generic drug business Actavis, forcing it to sell assets.
The higher costs have led to rationing of dwindling supplies of the less expensive
generic drugs to avoid
purchasing the more expensive name brand treatments.
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS
Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the S
Drug Assistance Programs (ADAPs); continued fluctuations in ADAP
purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of
generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new
drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the S
drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
Amgen (# 13 this year, down from # 6 in 2011)
purchased Turkey's Mustafa Nevzat Pharmaceuticals, a maker of injectable
generic drugs, for $ 700 million.
«With the money saved from using
generic medicines, bulk
purchasing, and better approaches to pricing, we can afford to cover medically necessary
drugs for all Canadians without increasing taxes.»
Researchers found that increasing the use of
generic drugs and bringing Canadian
drug prices in line with other countries where universal
drug plans achieve better prices through bulk
purchasing and negotiation, would add up to significant savings.
When it comes to
generic prescription and OTC
drugs, paper towels, and various pantry staples such as flour (among other items), I will certainly
purchase the cheaper option.
CVS has also engaged in a joint venture with
drug distributor Cardinal Health Inc. to combine their
purchases of
generic drugs to extract a larger discount from manufacturers, which is generating higher margins.
Enrollees may be limited to buying
generic drugs, may have to deal with prior authorizations, or be sure that specific
drugs are covered under the policy they want to
purchase.
• Check out Squawkfox's latest price check experiment on
generic drugs, you could save up to 30 % on your
purchases.
The Jean Coutu Group were facing several challenges at the time including
drug distribution reform and the
purchase of a Quebec
generic drug manufacturer.
Professional Experience PCIVET (City, ST) Date — Date
Purchasing Manager / Buyer • Managed all
purchasing and procurement of branded and
generic prescription
drugs • Hired, trained, and directed support staff ensuring effective and efficient operations • Analyzed inventory movement, sales, and developed remedial strategies • Handled
purchasing negotiations to secure quality products at competitive prices • Researched and evaluated product quality and sales potential prior to
purchase
We worried that the cash would just immediately go back to the
drug trade so decided that we would
purchase a
generic card and write sorry in it and
purchase a few $ 250 gift cards to place in the card and give to the
drug dealers.